Pulmonary sequelae of treatment for breast cancer: A prospective study

Citation
Gc. Ooi et al., Pulmonary sequelae of treatment for breast cancer: A prospective study, INT J RAD O, 50(2), 2001, pp. 411-419
Citations number
35
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
03603016 → ACNP
Volume
50
Issue
2
Year of publication
2001
Pages
411 - 419
Database
ISI
SICI code
0360-3016(20010601)50:2<411:PSOTFB>2.0.ZU;2-9
Abstract
Purpose: To prospectively study the effects of loco-regional radiotherapy i n women with breast cancer. Methods and Materials: Thirty consecutive patients with breast resection un derwent clinical, lung function, radiographic, and thoracic high-resolution computed tomography evaluation before and at 1, 3, 6, and 12 months after adjuvant radiotherapy. Chemotherapy was also administered to 15 patients. Results: Nineteen patients reported mild respiratory symptoms at 1 month, w hich resolved completely at 6 months after radiotherapy, Opacities were pre sent on 80% of chest radiographs and in all patients on high-resolution com puted tomography by 3 months. These opacities became compact and persisted on high-resolution computed tomography at 12 months. Lung function indices, including FEV1, FVC, TLC, and DLCO, progressively declined after radiother apy, and was irreversible at 12 months (p < 0.05), Patients who received ch emotherapy did not have significantly different lung function indices compa red with their counterparts at all time points (p > 0.05). Conclusions: Our results have shown that adjuvant loco-regional radiotherap y, a common practice in breast cancer treatment, is associated with irrever sible reduction in lung function parameters. These changes are accompanied by radiological evidence of persistent lung injury. Further studies should be performed to evaluate the incidence and long-term pulmonary sequelae of current treatment for breast cancer, (C) 2001 Elsevier Science Inc.